- Home
- SBLK vs VRDN Comparison
SBLK vs VRDN Comparison
Compare SBLK & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBLK
- VRDN
- Stock Information
- Founded
- SBLK 2006
- VRDN 2006
- Country
- SBLK Greece
- VRDN United States
- Employees
- SBLK N/A
- VRDN N/A
- Industry
- SBLK Marine Transportation
- VRDN Medical Specialities
- Sector
- SBLK Consumer Discretionary
- VRDN Health Care
- Exchange
- SBLK Nasdaq
- VRDN Nasdaq
- Market Cap
- SBLK 1.9B
- VRDN 1.6B
- IPO Year
- SBLK N/A
- VRDN N/A
- Fundamental
- Price
- SBLK $15.65
- VRDN $13.07
- Analyst Decision
- SBLK Strong Buy
- VRDN Buy
- Analyst Count
- SBLK 3
- VRDN 12
- Target Price
- SBLK $22.67
- VRDN $36.44
- AVG Volume (30 Days)
- SBLK 2.0M
- VRDN 761.8K
- Earning Date
- SBLK 05-21-2025
- VRDN 05-07-2025
- Dividend Yield
- SBLK 13.75%
- VRDN N/A
- EPS Growth
- SBLK 60.00
- VRDN N/A
- EPS
- SBLK 2.80
- VRDN N/A
- Revenue
- SBLK $1,265,458,000.00
- VRDN $302,000.00
- Revenue This Year
- SBLK N/A
- VRDN N/A
- Revenue Next Year
- SBLK $18.23
- VRDN $20,553.29
- P/E Ratio
- SBLK $5.61
- VRDN N/A
- Revenue Growth
- SBLK 33.31
- VRDN N/A
- 52 Week Low
- SBLK $14.30
- VRDN $11.40
- 52 Week High
- SBLK $27.47
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- SBLK 44.24
- VRDN 33.48
- Support Level
- SBLK $15.24
- VRDN $14.03
- Resistance Level
- SBLK $15.81
- VRDN $15.91
- Average True Range (ATR)
- SBLK 0.44
- VRDN 0.67
- MACD
- SBLK -0.13
- VRDN -0.19
- Stochastic Oscillator
- SBLK 19.52
- VRDN 18.61
About SBLK Star Bulk Carriers Corp.
Star Bulk Carriers Corp provides seaborne transportation solutions in the dry bulk sector. The company owns and operates dry bulk carrier vessels, which are used to transport bulk, such as iron ore, coal, grains, bauxite, fertilizers, and steel products. It owns a fleet of vessels that consists of Newcastlemax, Capesize, Post Panamax, Kamsarmax, Panamax, Ultramax, and Supramax. It generates revenues through the voyages it carries out.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.